FDA 483 - AMARIN PHARMACEUTICALS, INC - June 04, 2001

An FDA inspection of Amarin Pharmaceuticals, Inc. in Warren, NJ on June 4, 2001, identified one observation. The firm was cited for an inadequate written procedure regarding the surveillance, receipt, evaluation, and reporting of adverse drug experiences. This indicates a deficiency in their pharmacovigilance processes.